Atherosclerosis: The cost of illness in Portugal

Costa, João; Alarcão, Joana; Amaral‐Silva, Alexandre; Araújo, Francisco; Ascenção, Raquel; Caldeira, Daniel; Cardoso, Miguel; Correia, Manuel; Fiorentino, F; Gavina, Cristina; Gil, Víctor; Gouveia, Miguel; Lourenço, F.; Silva, Alberto Mello e; Pedro, Luís Mendes; Vaz‐Carneiro, António; Veríssimo, Manuel Teixeira; Borges, Margarida

doi:10.1016/j.repce.2020.08.003

Cited by 6 publications

(6 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Um bom exemplo é o custo associado com a aterosclerose que se constitui no denominador patológico comum às principais causas de morbimortalidade dos países desenvolvidos, incluindo, entre outras, as síndromes coronarianas agudas e crônicas, os AVC isquêmicos e a doença arterial periférica. Em artigo publicado na RPC, Costa et al 19 procuraram quantificar o impacto econômico da aterosclerose em Portugal, usando para isso dados de prevalência e recorrendo a múltiplas bases de dados nacionais. Os custos da aterosclerose totalizaram 1,9 mil milhões de euros por ano, o que corresponde a 11% de todos os gastos em saúde e a aproximadamente 1% do PIB (dados de 2016).…”

Section: Covid-19 E Suas Consequênciasunclassified

“…Como mencionado, o maior custo das doenças ateroscleróticas, por paciente, relaciona-se com a doença cardíaca isquêmica e sua abordagem, notadamente devido às diferentes terapêuticas disponíveis. 19 Vários estudos mostraram que a avaliação funcional invasiva coronária com reserva fracionada de fluxo miocárdico (do inglês fractional flow reserve, FFR ou iFFR) pode ser custo-efetiva 20 e melhorar o prognóstico. [21][22][23] Contudo, a sua utilização na prática clínica é ainda residual na maioria dos laboratórios de cardiologia de intervenção.…”

Section: Desafios Atuais Na Doença Arterial Coronarianaunclassified

See 1 more Smart Citation

Os Melhores Artigos do Ano 2021 nos Arquivos Brasileiros de Cardiologia e na Revista Portuguesa de Cardiologia

Fontes‐Carvalho

Oliveira

Gonçalves-Teixeira

et al. 2022

Arquivos Brasileiros De Cardiologia

View full text Add to dashboard Cite

Section: Covid-19 E Suas Consequênciasunclassified

Section: Desafios Atuais Na Doença Arterial Coronarianaunclassified

Os Melhores Artigos do Ano 2021 nos Arquivos Brasileiros de Cardiologia e na Revista Portuguesa de Cardiologia

Fontes‐Carvalho

Oliveira

Gonçalves-Teixeira

et al. 2022

Arquivos Brasileiros De Cardiologia

View full text Add to dashboard Cite

“…Both CVD [ 6 , 7 ] and ASCVD are specifically associated with significant morbidity and mortality [ 3 , 8 , 9 ], as well as a substantial economic burden [ 10 – 13 ]. Most of the available evidence on the economic burden of ASCVD focuses on healthcare resource utilization and the direct costs associated with both acute and long-term medical care [ 11 – 13 ], whereas few studies evaluate indirect costs at an individual level.…”

Section: Introductionmentioning

confidence: 99%

“…A small number of cost-of-illness studies have shown that ASCVD is associated with indirect costs due to lost productivity [ 10 , 14 – 17 ]; however, these studies typically rely on imprecise aggregate data and are often based on small studies or expert opinion. Moreover, cost-of-illness studies typically present data on costs in one year for a prevalent population.…”

Section: Introductionmentioning

confidence: 99%

Economic burden of atherosclerotic cardiovascular disease: a matched case–control study in more than 450,000 Swedish individuals

Steen Carlsson,

Nilsson,

Wolden

et al. 2023

BMC Cardiovasc Disord

View full text Add to dashboard Cite

Aim To examine direct and indirect costs, early retirement, cardiovascular events and mortality over 5 years in people with atherosclerotic cardiovascular disease (ASCVD) and matched controls in Sweden. Methods Individuals aged ≥ 16 years living in Sweden on 01 January 2012 were identified in an existing database. Individuals with ASCVD were propensity score matched to controls without ASCVD by age, sex and educational status. We compared direct healthcare costs (inpatient, outpatient and drug costs), indirect costs (resulting from work absence) and the risk of stroke, myocardial infarction (MI) and early retirement. Results After matching, there were 231,417 individuals in each cohort. Total mean per-person annual costs were over 2.5 times higher in the ASCVD group versus the controls (€6923 vs €2699). Indirect costs contributed to 60% and 67% of annual costs in the ASCVD and control groups, respectively. Inpatient costs accounted for ≥ 70% of direct healthcare costs. Cumulative total costs over the 5-year period were €32,011 in the ASCVD group and €12,931 in the controls. People with ASCVD were 3 times more likely to enter early retirement than controls (hazard ratio [HR] 3.02 [95% CI 2.76–3.31]) and approximately 2 times more likely to experience stroke (HR 1.83 [1.77–1.89]) or MI (HR 2.27 [2.20–2.34]). Conclusion ASCVD is associated with both economic and clinical impacts. People with ASCVD incurred considerably higher costs than matched controls, with indirect costs resulting from work absence and inpatient admissions being major cost drivers, and were also more likely to experience additional ASCVD events.

show abstract

“…Atherosclerotic cardiovascular diseases are one of the key causes of health care seeking, hospitalizations, temporary and permanent disability, and mortality in many countries of the world [ 2 , 3 , 4 ]. The economic and social burden associated with atherosclerosis, both globally and for individual patients, is considered to be so significant that it makes atherosclerosis the leading medical problem of our time [ 5 , 6 , 7 ]. It is important to note that atherosclerotic cardiovascular diseases are quite often diagnosed at clinically advanced stages, when therapeutic options are already limited and do not allow the achievement of a cure for all patients.…”

Section: Introductionmentioning

confidence: 99%

Immune Function of Endothelial Cells: Evolutionary Aspects, Molecular Biology and Role in Atherogenesis

Kotlyarov

2022

IJMS

View full text Add to dashboard Cite

Atherosclerosis is one of the key problems of modern medicine, which is due to the high prevalence of atherosclerotic cardiovascular diseases and their significant share in the structure of morbidity and mortality in many countries. Atherogenesis is a complex chain of events that proceeds over many years in the vascular wall with the participation of various cells. Endothelial cells are key participants in vascular function. They demonstrate involvement in the regulation of vascular hemodynamics, metabolism, and innate immunity, which act as leading links in the pathogenesis of atherosclerosis. These endothelial functions have close connections and deep evolutionary roots, a better understanding of which will improve the prospects of early diagnosis and effective treatment.

show abstract

Atherosclerosis: The cost of illness in Portugal

Cited by 6 publications

References 10 publications

Os Melhores Artigos do Ano 2021 nos Arquivos Brasileiros de Cardiologia e na Revista Portuguesa de Cardiologia

Os Melhores Artigos do Ano 2021 nos Arquivos Brasileiros de Cardiologia e na Revista Portuguesa de Cardiologia

Economic burden of atherosclerotic cardiovascular disease: a matched case–control study in more than 450,000 Swedish individuals

Immune Function of Endothelial Cells: Evolutionary Aspects, Molecular Biology and Role in Atherogenesis

Contact Info

Product

Resources

About